Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment

Lei Huang,Jialu Shao,Wenwen Lai,Hongfeng Gu,Jieping Yang,Shi Shi,Shepherd Wufoyrwoth,Zhe Song,Yi Zou,Yungen Xu,Qihua Zhu

DOI: https://doi.org/10.1016/j.ejmech.2024.116159

IF: 7.088

2024-02-03

European Journal of Medicinal Chemistry

Abstract:The first examples of ataxia telangiectasia and Rad3-related (ATR) PROTACs were designed and synthesized. Among them, the most potent degrader, ZS-7 , demonstrated selective and effective ATR degradation in ATM-deficient LoVo cells, with a DC 50 value of 0.53 μM. Proteasome-mediated ATR degradation by ZS-7 lasted approximately 12 h after washout in the LoVo cell lines. Notably, ZS-7 demonstrated reasonable PK profiles and, as a single agent or in combination with cisplatin, showed improved antitumor activity and safety profiles compared with the parent inhibitor AZD6738 in a xenograft mouse model of LoVo human colorectal cancer cells upon intraperitoneal (i.p.) administration.

chemistry, medicinal